Albert Ribera

Centre for Research on Ecology and Forestry Applications — Spain

Medicine · Health Sciences

17h-index1.5kcitations43works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lysosomal Storage Disorders Research(9), HIV Research and Treatment(6), Retinal Development and Disorders(5), Pneumocystis jirovecii pneumonia detection and treatment(5), HIV/AIDS Research and Interventions(4)

Publications43 total

Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy
Molecular Therapy·2024· 13 citedOpen Access
898-P: AAV-FGF21 Gene Therapy Extends Healthspan in Old Mice
Diabetes·2024· 1 cited
883-P: Brain-Directed AAV-FGF21 Gene Therapy Reverses Type 2 Diabetes, Obesity, and Cognitive Decline
Diabetes·2024
838-P: Reversion of Nonalcoholic Steatohepatitis by Skeletal-Muscle Directed FGF21 Gene Therapy
Diabetes·2023
Une sépulture de masse de la peste justinienne découverte dans l’aire funéraire épiscopale de Valentia (Espagne) – version abrégée
Presses universitaires de Provence eBooks·2023
Justinian plague mass grave found in Valentia’s episcopal cemetery
Presses universitaires de Provence eBooks·2023
Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal
Molecular Therapy — Methods & Clinical Development·2021· 31 citedOpen Access
Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy
Nature Communications·2021· 35 citedOpen Access
FGF21 gene therapy as treatment for obesity and insulin resistance
EMBO Molecular Medicine·2018· 321 citedOpen Access
Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID
Human Molecular Genetics·2017· 50 citedOpen Access
Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC
Disease Models & Mechanisms·2016· 27 citedOpen Access
CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)
JCI Insight·2016· 61 citedOpen Access
348. Correction of CNS and Somatic Pathology by Intra-Cerebrospinal Fluid Gene Therapy for Mucopolysaccharidosis Type II
Molecular Therapy·2016Open Access
ribera et al 2015 supp mat
2015
Biochemical, histological and functional correction of mucopolysaccharidosis Type IIIB by intra-cerebrospinal fluid gene therapy
Human Molecular Genetics·2014· 53 citedOpen Access
Pompéi. Boutique VII 4, 26
Chronique des activités archéologiques de l’École française de Rome·2014· 1 citedOpen Access
AAV8-mediated Sirt1 gene transfer to the liver prevents high carbohydrate diet-induced nonalcoholic fatty liver disease
Molecular Therapy — Methods & Clinical Development·2014· 34 citedOpen Access
In Vivo Adeno-Associated Viral Vector–Mediated Genetic Engineering of White and Brown Adipose Tissue in Adult Mice
Diabetes·2013· 89 citedOpen Access
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Journal of Clinical Investigation·2013· 229 citedOpen Access
Insulin-like Growth Factor I (IGF-I)-induced Chronic Gliosis and Retinal Stress Lead to Neurodegeneration in a Mouse Model of Retinopathy
Journal of Biological Chemistry·2013· 23 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Fátima Bosch(24), Miquel García(16), Virginia Haurigot(16), Sara Marcó(13), Xavier León(12), Jesús Ruberte(12), Pilar Villacampa(12), Tor J(10), Sandra Motas(9), Maria Molas(9), Carles Roca(9), Víctor Sánchez(9), Verónica Jiménez(7), Ivet Elias(7), Tura Ferré(7), Roberto Muga(7), Vincent Soriano(7), Claudia Jambrina(6), Estefanía Casana(6), Sergio Muñoz(6)